Bexarotene and DAB₃₈₉IL-2 (Denileukin Diftitox, ONTAK) in Treatment of Cutaneous T-Cell Lymphomas: Algorithms

Medicine & Life Sciences

• denileukin diftitox 100%
• Bexarotene 90%
• Cutaneous T-Cell Lymphoma 71%
• Mycosis Fungoides 21%
• Ficusin 15%
• Skin 12%
• T-Lymphocytes 10%
• Therapeutics 9%
• Gels 9%
• Capillary Leak Syndrome 8%
• Photopheresis 8%
• Retinoid X Receptors 7%
• Quality of Life 7%
• Phototherapy 6%
• Interleukin-2 Receptors 6%
• Retinoids 6%
• Lymphadenopathy 5%
• Interferon-alpha 5%
• Psoriasis 5%
• Leukocyte Count 5%
• Methotrexate 5%
• Intravenous Administration 5%
• Capsules 4%
• Oral Administration 4%
• Lymphoma 4%
• Thyroid Gland 4%
• Electrons 4%
• Steroids 4%
• Maintenance 3%
• Lipids 3%
• Cytokines 3%
• Drug Therapy 3%
• Survival 3%
• Neoplasms 1%